OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Respiratory and Critical Care Medicine is 86. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome	1005
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline	745
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study	627
COVID-19 with Different Severities: A Multicenter Study of Clinical Features	590
Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline	489
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline	485
Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2	465
Characterization of the Inflammatory Response to Severe COVID-19 Illness	436
Why COVID-19 Silent Hypoxemia Is Baffling to Physicians	415
Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease	393
Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19	371
COVID-19–related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids	323
Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study	318
Endothelial Responses in Sepsis	283
A Single-Cell Atlas of the Human Healthy Airways	267
COVID-19–associated Pulmonary Aspergillosis	266
Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2	254
Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2	249
Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis	231
Tissue-Specific Immunopathology in Fatal COVID-19	226
Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations	225
Lung Recruitability in COVID-19–associated Acute Respiratory Distress Syndrome: A Single-Center Observational Study	217
Basing Respiratory Management of COVID-19 on Physiological Principles	202
Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective	198
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis	197

Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline	191
Lung Microbiota Predict Clinical Outcomes in Critically Ill Patients	191
Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis	190
Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium	188
Symptoms of Anxiety, Depression, and Peritraumatic Dissociation in Critical Care Clinicians Managing Patients with COVID-19. A Cross-Sectional Study	182
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes	179
High-Flow Nasal Cannula in Critically III Patients with Severe COVID-19	173
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study	159
SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients	158
Lung- and Diaphragm-Protective Ventilation	151
Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome	149
Mechanical Ventilation in COVID-19: Interpreting the Current Epidemiology	149
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele	144
Early Inspiratory Effort Assessment by Esophageal Manometry Predicts Noninvasive Ventilation Outcome in De Novo Respiratory Failure. A Pilot Study	143
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial	140
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease	140
Ventilatory Variables and Mechanical Power in Patients with Acute Respiratory Distress Syndrome	135
The Structural and Social Determinants of the Racial/Ethnic Disparities in the U.S. COVID-19 Pandemic. What’s Our Role?	135
Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease	132
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications	131
Air Pollution, Genetic Factors, and the Risk of Lung Cancer: A Prospective Study in the UK Biobank	128
Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection	126
Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline	125
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study	124
Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU	124
Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline	123
Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement	120
Static and Dynamic Contributors to Ventilator-induced Lung Injury in Clinical Practice. Pressure, Energy, and Power	119
Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids	116
An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal	114
Respiratory Mechanics of COVID-19– versus Non–COVID-19–associated Acute Respiratory Distress Syndrome	113
From GOLD 0 to Pre-COPD	110
Aerosol Generation from the Respiratory Tract with Various Modes of Oxygen Delivery	110
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical	109
Effect of Lowering Vt on Mortality in Acute Respiratory Distress Syndrome Varies with Respiratory System Elastance	108
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary	107
Ineffectual Type 2–to–Type 1 Alveolar Epithelial Cell Differentiation in Idiopathic Pulmonary Fibrosis: Persistence of the KRT8^hi Transitional State	105
Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia	104
Effect of Weight Loss on Upper Airway Anatomy and the Apnea–Hypopnea Index. The Importance of Tongue Fat	102
Assessing the Accuracy of a Deep Learning Method to Risk Stratify Indeterminate Pulmonary Nodules	101
Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study	101
Sleep Apnea–Specific Hypoxic Burden, Symptom Subtypes, and Risk of Cardiovascular Events and All-Cause Mortality	101
Machine Learning Classifier Models Can Identify Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data	101
Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis	100
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision	100
Single-Cell Reconstruction of Human Basal Cell Diversity in Normal and Idiopathic Pulmonary Fibrosis Lungs	99
Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency	99
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis	99
Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease	98
Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia	97

Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland	94
Mitigating Inequities and Saving Lives with ICU Triage during the COVID-19 Pandemic	94
Mechanical Ventilation for Acute Respiratory Distress Syndrome during Extracorporeal Life Support. Research and Practice	94
Injury to the Endothelial Glycocalyx in Critically Ill Patients with COVID-19	89
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension	89
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial	89
Sleep Apnea and COVID-19 Mortality and Hospitalization	88
The Early Change in Pa_CO₂after Extracorporeal Membrane Oxygenation Initiation Is Associated with Neurological Complications	88
New Physical, Mental, and Cognitive Problems 1 Year after ICU Admission: A Prospective Multicenter Study	88
Characterization of Disease Phenotype in Very Preterm Infants with Severe Bronchopulmonary Dysplasia	86
High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-19	86
The Sleep Apnea–Specific Pulse-Rate Response Predicts Cardiovascular Morbidity and Mortality	86